Company / Operating Income
aTYR PHARMA INC Operating Income History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$77.6M
FY2025
5-year range
-$77.6M / -$15.9M
FY2021-FY2025
Trend
-14.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 3 consecutive years, from -$16M in FY2022 to -$78M in FY2025.
Based on SEC 10-K filings.
-$78M in FY2025.
Declined from -$34M to -$78M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- aTYR PHARMA INC's operating income has declined for 3 consecutive years.
- In FY2025, operating income decreased 14.3% year-over-year.
- Peak operating income was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$77.6M | -14.3% |
| FY2024 | -$67.9M | -99.7% |
| FY2023 | -$34.0M | -113.8% |
| FY2022 | -$15.9M | +30.8% |
| FY2021 | -$23.0M | +30.0% |
| FY2020 | -$32.8M | +30.4% |
| FY2019 | -$47.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026